Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 118

Sort by

Sort Order Select

Journal Articles

Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis

Muhammad Kashif Amin, Moazzam Shahzad, Matthew McGuirk, Asma Zakir, Al-Ola Abdallah, Nausheen Ahmed, Sunil Abhyankar, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

Blood (2025) 146 (Supplement 1): 173.

https://doi.org/10.1182/blood-2025-173

Published: 2025

Journal Articles

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study

Amir Ali, Pallawi Torka, Yucai Wang, Tara Graff, Erin Mulvey, Yumeng Zhang, Monika Jun, Abualbishr Alshreef, Alex Mutebi, Anthony Wang, David Tybor, Lynn Huynh, Angela Lax, Tychell Branchcomb, Mei Sheng Duh, Javier Munoz, Muhamad Alhaj Moustafa, Nausheen Ahmed

Blood (2025) 146 (Supplement 1): 8075.

https://doi.org/10.1182/blood-2025-8075

Published: 2025

Journal Articles

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy

Raeef Rahman, Isuru Ratnayake, Jianzheng Wu, Lauren Scott, William Wesson, Razan Mansour, Marc Hoffmann, Aung Tun, Joseph Bennett, Al-Ola Abdallah, Muhammad Mushtaq, Dinesh Mudaranthakam, Joseph McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2025) 146 (Supplement 1): 7630.

https://doi.org/10.1182/blood-2025-7630

Published: 2025

Journal Articles

Parkinsonism and other non-immune effector cell-associated neurotoxicities related to BCMA-directed chimeric antigen receptor T-cell therapy

Paul Worsley, Jianzheng Wu, Isuru Ratnayake, Dinesh Mudaranthakam, Al-Ola Abdallah, Jeries Kort, Evguenia Bhurtel, Leyla Shune, Joseph McGuirk, Muhammad Nashatizadeh, Nausheen Ahmed, Forat Lutfi

Blood (2025) 146 (Supplement 1): 2389.

https://doi.org/10.1182/blood-2025-2389

Published: 2025

Journal Articles

The durability of consolidative transplant in mediastinal gray zone lymphoma, a single institution retrospective

Neda Amirmokhtari, Jianzheng Wu, Marc Hoffmann, Aung Tun, Joseph Bennett, Nausheen Ahmed, Muhammad Umair Mushtaq, Shaun DeJarnette, Forat Lutfi

Blood (2025) 146 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2025-7197

Published: 2025

Journal Articles

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Blood (2025) 146 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2025-1798

Published: 2025

Journal Articles

Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications

Yuanli Lei, Muhammad Atif Khan, Aqsa Ashraf, Noha Soror, Muhammad Salman Faisal, Jennifer Holter-Chakrabarty, Adam Asch, Forat Lutfi, Rachel Dileo, Sami Ibrahimi, Manu Pandey, Mohamad Khawandanah, Silas Day, Huimin Wu, Prerna Mewawalla, Nausheen Ahmed, Taha Al-Juhaishi

Blood (2025) 146 (Supplement 1): 2373.

https://doi.org/10.1182/blood-2025-2373

Published: 2025

Journal Articles

Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis

Muhammad Atif Khan, Zafar Ali, Abat Khan, Faiza Humayun Khan, Nausheen Ahmed

Blood (2025) 146 (Supplement 1): 7841.

https://doi.org/10.1182/blood-2025-7841

Published: 2025

Journal Articles

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Blood (2025) 146 (Supplement 1): 133.

https://doi.org/10.1182/blood-2025-133

Published: 2025

Journal Articles

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Blood (2025) 146 (8): 1011–1029.

https://doi.org/10.1182/blood.2024027197

Published: 2025

Includes: Supplemental data

Journal Articles

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Blood (2025) 146 (2): 167–177.

https://doi.org/10.1182/blood.2024026216

Published: 2025

Includes: Supplemental data

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology

Emily J Casteen, Lauren N Scott, Raeef L Rahman, Zahra Mahmoudjafari, Faiz Anwer, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Al-Ola Abdallah, Shebli Atrash, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7950.

https://doi.org/10.1182/blood-2024-204130

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Jordan Snyder, Nausheen Ahmed, Aqeeb Ur Rehman, Muhammad Umair Mushtaq, Aung M. Tun, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7731.

https://doi.org/10.1182/blood-2024-207753

Published: 2024

Journal Articles

Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Bone Marrow Transplantation

Sibgha Gull Chaudhary, Moazzam Shahzad, Iqra Anwar, Sohaib Irfan, Muhammad Kashif Amin, Matthew McGuirk, Shaun DeJarnette, Nausheen Ahmed, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7424.

https://doi.org/10.1182/blood-2024-198378

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Raeef L Rahman, Jianzheng Wu, Lauren N Scott, William Wesson, Razan Mansour, Aung M. Tun, Marc Hoffmann, Al-Ola Abdallah, Dinesh Pal Mudaranthakam, Joseph P. McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7099.

https://doi.org/10.1182/blood-2024-205978

Published: 2024

Journal Articles

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Blood (2024) 144 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2024-207398

Published: 2024

Journal Articles

Impact of Obesity on Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation

Moazzam Shahzad, Aleenah Mohsin, Aqeeb Ur Rehman, Sohaib Irfan, Muhammad Atif Khan, Muhammad Kashif Amin, Matthew McGuirk, Sibgha Gull Chaudhary, Faiza Humayun Khan, Iqra Anwar, Nausheen Ahmed, Al-Ola Abdallah, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7421.

https://doi.org/10.1182/blood-2024-193485

Published: 2024

Journal Articles

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Ishita Kamboj, Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, James A Davis, Aliya Rashid, Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Abdullah Mohammad Khan, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 2411.2.

https://doi.org/10.1182/blood-2024-199187

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Abdullah Mohammad Khan, Al-Ola Abdallah, Nausheen Ahmed, Shebli Atrash, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2024-208692

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy

Parkinsonism and other non-immune effector cell-associated neurotoxicities related to BCMA-directed chimeric antigen receptor T-cell therapy

The durability of consolidative transplant in mediastinal gray zone lymphoma, a single institution retrospective

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications

Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Exploring the Global Landscape of Open Access Publication Models and Their Correlation with the Impact Factor in the Field of Hematology/Oncology

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Bone Marrow Transplantation

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Impact of Obesity on Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only